CareDx Inc CDNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
CareDx Announces Third KOAR Analysis Published in Transplantation
CareDx Announces Third Quarter 2026 Financial Results
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
Trading Information
- Previous Close Price
- $76.33
- Day Range
- $76.56–79.99
- 52-Week Range
- $14.45–90.54
- Bid/Ask
- $78.36 / $79.38
- Shares Outstanding
- 52.54M
- Market Cap
- $4.22B
- Volume/Avg
- 140,882 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 25.99
- Price/Sales
- 8.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.61%
Company Profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 765
- Website
- https://www.caredx.com
Valuation
Metric | CDNA |
|---|---|
Price/Earnings (Normalized) | 25.99 |
Price/Book Value | 8.57 |
Price/Sales | 8.21 |
Price/Cash Flow | 58.50 |
Price/Earnings
CDNA
Financial Strength
Metric | CDNA |
|---|---|
Quick Ratio | 2.15 |
Current Ratio | 2.31 |
Interest Coverage | — |
Quick Ratio
CDNA
Profitability
Metric | CDNA |
|---|---|
Return on Assets (Normalized) | 15.14% |
Return on Equity (Normalized) | 20.22% |
Return on Invested Capital (Normalized) | 17.40% |
Return on Assets
CDNA
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|Hn!NcjK | LOCK|&s | $251B | |||
| Danaher Corp DHR | LOCK|^$gRl%f | LOCK|<NR | $159B | |||
| IDEXX Laboratories Inc IDXX | LOCK|@^@lj>F? | LOCK|#h@ | $53B | |||
| Agilent Technologies Inc A | LOCK|$&kYCnxc | LOCK|#Zr | $48B | |||
| Waters Corp WAT | LOCK|Kt<B@#@ | LOCK|!H | $44B | |||
| IQVIA Holdings Inc IQV | LOCK|&?r<?l? | LOCK|MySs | $44B | |||
| Mettler-Toledo International Inc MTD | LOCK|mnsPlmx | LOCK|?QCd | $34B | |||
| Illumina Inc ILMN | LOCK|fbrvYQC | LOCK|<&YJT | $31B | |||
| Labcorp Holdings Inc LH | LOCK|tyKK>$? | LOCK|$Yjw# | $29B | |||
| Quest Diagnostics Inc DGX | LOCK|l<mgS? | LOCK|G$!n | $28B |
United States